retatrutide nonalcoholic steatohepatitis trial Retatrutide: A Promising Breakthrough for Fatty Liver Disease Retatrutide for weight loss: Study

In fact, research suggests that after stopping GLP-1 medications, around 60% of people will regain the weight theyve lost

The most common side effects are gastrointestinal, including nausea (affecting 15-50% of patients), vomiting, diarrhoea, constipation, and abdominal discomfort

Glucagon receptor activation increases hepatic glucose output and, at doses balanced against GLP-1R-mediated insulin secretion, raises basal metabolic rate by 10 to 20% in preclinical models without net hyperglycemia

Acknowledgments We thank the participants for their cooperation and support

Compared to solid foods, options like soups, smoothies, and porridge are often easier to tolerate